Navigation Links
Bedford Laboratories(TM) to Begin Shipping Sumatriptan Succinate Injection
Date:2/25/2009

BEDFORD, Ohio, Feb. 25 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., today announced the launch of Sumatriptan Succinate Injection. This product is AP rated and is equivalent to Imitrex(R) by GlaxoSmithKline. Sumatriptan is a vascular headache suppressant indicated for 1) the acute treatment of migraine attacks with or without aura and 2) the acute treatment of cluster headache episodes. Sumatriptan Succinate Injection is not for use in the management of hemiplegic or basilar migraine.

(LOGO: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO)

Bedford Laboratories will supply Sumatriptan Succinate Injection as a sterile aqueous solution in a 6mg (Base) / 0.5mL single-dose vial packaged in cartons containing 10 vials.

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169 or at www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim Corporation

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on the Boehringer Ingelheim Corporation, please visit http://us.boehringer-ingelheim.com.

Imitrex is a registered trademark of GlaxoSmithKline


'/>"/>
SOURCE Bedford Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bedford Laboratories(TM) to Begin Shipping Irinotecan HCl Injection
2. Children of New Bedford Immigrant Raids Are Victims of Terrorism, Testifies Dr. Laria Today
3. Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution
4. MidMichigan Health Cuts Out Trans Fats Beginning March 1
5. Disability Community Humble Beginnings Lead to Great Things at Disabled World
6. Perrigo Begins Shipments of Ibuprofen PM
7. Governor Crist Proclaims Tobacco Free Florida Week Beginning February 27
8. Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors
9. First Electronic Healthcare Network in the U.S. Begins Operations in Buffalo, NY
10. U.S. Labor Department to begin new monthly data series on people with disabilities from Current Population Survey on Feb. 6
11. Milkscreen Home Test for Alcohol in Breast Milk Begins Nationwide Sales at Walgreens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology: